Physician profile
Michael Avery
NPI 1255568069
$2,346.73
in general payments reported to CMS, 2019-2025
18 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $329 · 2021: $293 · 2022: $241 · 2023: $434 · 2024: $448 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.02 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.82 | 2019-2025 | Rinvoq |
| Amgen INC. | $178.11 | 2019-2025 | Enbrel, Otezla, Amjevita |
| Novartis Pharmaceuticals Corporation | $108.65 | 2023-2025 | |
| Genentech USA, INC. | $85.15 | 2024-2025 | Actemra |
| Lilly USA, LLC | $81.03 | 2023-2025 | Taltz |
| Glaxosmithkline, LLC. | $64.88 | 2020-2023 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $44.47 | 2024-2025 | Saphnelo |
| Janssen Biotech, INC. | $36.31 | 2022-2024 | Tremfya |
| Tg Therapeutics, INC. | $27.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.51 | 2025 | Orencia |
| Octapharma USA, INC. | $24.34 | 2024 | Panzyga |
| Sobi, INC | $19.25 | 2023 | |
| Sandoz INC. | $19.06 | 2024 | Hyrimoz |
| Abbott Laboratories | $17.75 | 2025 | Infinity |
| US Oncology Corporate, INC. | $16.61 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.68 | 2020 | |
| Horizon Therapeutics Plc | $13.62 | 2021 | |
| Electronic Waveform Lab, INC. | $5.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.